egnite Inc.02.04.22
egnite Inc.'s flagship product, CardioCare, can now be used to treat heart failure patients.
The company is leveraging real-world insights to help doctors identify at-risk patients with heart failure and a reduced ejection fraction (HFrEF) who are not on guideline-directed medication and could benefit from timely intervention. “Healthcare information is moving rapidly with estimates of doubling five times a year. Data-driven population health initiatives like this are imperative to assist providers in managing their patients to the highest level of guideline-based care, the foundation of heart failure management. This work will improve patient management, quality of care, and save lives,” said John Mignone, M.D., Ph.D., Robert M. and Patricia Arnold Endowed medical director for Heart Failure and co-executive medical director at Swedish Heart and Vascular Institute.
Early data from five heart programs managing more than 50,000 HFrEF patients indicate the three-year survival rates for HFrEF patients prescribed 0 or 4 guideline-directed medications were 56 percent and 95 percent, respectively. Thirty-day hospital readmissions for HFrEF patients prescribed 0 guideline-directed medications were three times higher than patients prescribed 4 medications, at 18 percent and 6 percent, respectively.
These real-world insights from the CardioCare platform indicate an average of only 2.48 percent HFrEF patients are prescribed all 4 guideline-directed medications to manage their disease. “These data demonstrate significant opportunity to help improve survival and reduce readmission rates for heart failure patients,” said Joel Portice, CEO of egnite. “CardioCare’s first to market technology helps hospital systems understand and improve the care for these large heart failure patent populations.”
CardioCare partners with more than 50 heart programs to reduce variability in care and improve guideline-directed treatment for patients with heart valve disease. This expansion into heart failure is the first of many for CardioCare as egnite continues its pursuit to elevate the standard of structural heart patient care by bringing leading-edge technologies to hospital systems.
egnite is a digital health company focused on providing artificial intelligence solutions to help hospitals identify and manage their most at-risk patients. The company’s flagship AI platform, CardioCare, has partnered with more than 50 hospitals nationwide and leverages the program’s big data analytics platform of over one million echocardiograms to elevate the standard of patient care. The company is based in Aliso Viejo, Calif.
The company is leveraging real-world insights to help doctors identify at-risk patients with heart failure and a reduced ejection fraction (HFrEF) who are not on guideline-directed medication and could benefit from timely intervention. “Healthcare information is moving rapidly with estimates of doubling five times a year. Data-driven population health initiatives like this are imperative to assist providers in managing their patients to the highest level of guideline-based care, the foundation of heart failure management. This work will improve patient management, quality of care, and save lives,” said John Mignone, M.D., Ph.D., Robert M. and Patricia Arnold Endowed medical director for Heart Failure and co-executive medical director at Swedish Heart and Vascular Institute.
Early data from five heart programs managing more than 50,000 HFrEF patients indicate the three-year survival rates for HFrEF patients prescribed 0 or 4 guideline-directed medications were 56 percent and 95 percent, respectively. Thirty-day hospital readmissions for HFrEF patients prescribed 0 guideline-directed medications were three times higher than patients prescribed 4 medications, at 18 percent and 6 percent, respectively.
These real-world insights from the CardioCare platform indicate an average of only 2.48 percent HFrEF patients are prescribed all 4 guideline-directed medications to manage their disease. “These data demonstrate significant opportunity to help improve survival and reduce readmission rates for heart failure patients,” said Joel Portice, CEO of egnite. “CardioCare’s first to market technology helps hospital systems understand and improve the care for these large heart failure patent populations.”
CardioCare partners with more than 50 heart programs to reduce variability in care and improve guideline-directed treatment for patients with heart valve disease. This expansion into heart failure is the first of many for CardioCare as egnite continues its pursuit to elevate the standard of structural heart patient care by bringing leading-edge technologies to hospital systems.
egnite is a digital health company focused on providing artificial intelligence solutions to help hospitals identify and manage their most at-risk patients. The company’s flagship AI platform, CardioCare, has partnered with more than 50 hospitals nationwide and leverages the program’s big data analytics platform of over one million echocardiograms to elevate the standard of patient care. The company is based in Aliso Viejo, Calif.